Attorney Docket No. Application No. 056291-5298 10/588,334 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Applicants: Craig JOHNSTONE et al. PTO Form 1449 September 24, 2008 Group Art Unit: 1614 Filing Date: August 3, 2006 U.S. PATENT DOCUMENTS Document No. Name Class Sub-Class Filing Date Initial Date US 3,917,625 November 4, 1975 Lee et al. 1. /PEZ/ 2. US 4,966,891 October 30, 1990 Fuiiu et al. US 6,242,474 June 5, 2001 Yamasaki et al. 3. US 6,255,335 July 3, 2001 Himmler et al. 4. February 19, 2002 5. US 6,348,474 Kayakiri et al. November 7, 2006 Kato et al. US 7,132,546 6. Hayter et al. US 7,199,140 April 3, 2007 7. June 12, 2007 Hargreaves et al. 8. US 7,230,108 9. US 20040077555 April 22, 2004 Ishihara et al. 10. US 20050148605 July 7, 2005 Grotzfeld et al. July 28, 2005 Grotzfeld et al. 11. US 20050165074 12. US 20050171171 August 4, 2005 Mehta et al. August 4, 2005 13. US 20050171172 Lai et al. US 20050261315 November 24, 2005 Mehta et al. 14. 15. US 20060004010 January 5, 2006 Habashita et al. July 27, 2006 US 20060167053 Iino et al. 16. US 20060258728 November 16, 2006 Tani et al. 17. FOREIGN PATENT DOCUMENTS Document No. Date Country Class Sub-Class Translation November 2, 2006 Canada CA 2605738 18. /PEZ/ EP 1132381 September 12, 2001 Europe 19. 20. September 20, 2006 EP 1702919 Europe United Kingdom 21. GB 1352415 May 8, 1974 22. WO 94/12461 June 9, 1994 WIPO 23. WO 99/17777 April 15, 1999 WIPO WIPO August 10, 2000 24. WO 00/46203 January 4, 2001 WIPO WO 01/00579 25. WIPO 26. WO 02/051831 July 4, 2002 27. WO 03/051366 June 26, 2003 WIPO WO 2004/022536 March 18, 2004 WIPO 28. WIPO 29. WO 2004/085385 October 7, 2004 December 23, 2004 WIPO 30. WO 2004/110350 June 2, 2005 WIPO 31. WO 2005/048953 CA 2605738 32. WO 2006/114180 November 2, 2006 **WIPO** WO 2006/125958 November 30, 2006 WIPO 33. WO 2006/125972 November 30, 2006 WIPO 34. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Date Considered Examiner 01/22/2009 /Paul Zarek/ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** ****		**************************************	Attorney Docket No. 056291-5298			Application No.			
INFO		TION DISCLOSUI				10/588,334			
	(U	se several sheets if nece	Applicants: Craig JOHNSTONE et al.						
		PTO Form 1449			T				
		September 24, 2008	Filing Date: August 3, 2006			Group Art Unit: 1614			
				Croup I at Came 2011					
U.S. PATENT DOCUMENTS									
Initial		Document No.	Date		Name	Class	Sub-Class	Filing Date	
FOREIGN PATENT DOCUMENTS									
/PEZ/		Document No.	Date		Country	Class	Sub-Class	Translation	
, , <u></u>	35.	WO 2007/007040	January 18, 2007		WIPO				
	36.	WO 2007/007041	January 18, 2007		WIPO				
	37.	WO 2007/007042	January 18, 2007		WIPO				
	38.	WO 2007/017649	February 15, 2007		WIPO				
i	39.	WO 2007/028135	March 8, 2007		WIPO				
	40.	WO 2007/031739	March 22, 2007		WIPO				
	41.	WO 2007/053657	May 10, 2007		WIPO				
	42.	WO 2007/060448	May 31, 2007		WIPO				
	43.	WO 2008/050101	May 2, 2008		WIPO				
-	44.	WO 2008/050117	May 2, 2008		WIPO				
	45.	WO 2008/075073	June 26, 2008		WIPO				
W									
-							.4		
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
/PEZ	46.	Brenner et al. "Imino-bridged heterocycles. VII. (1) N-aminobenzocycloheptapyridinimines" J. Heterocyclic Chem. 23:1331-1332 (1986)							
8	47.	Coghlan et al. "Glucokinase activators in diabetes management" Expert Opin. Investig. Drugs 17(2):145-167 (2008)							
00000	48.	Leighton, "Pre-clinical disease models – challenges and success stories" 44th Drug Information Association Annual							
2000	'	Meeting, Boston, MA, US (2008)							
i i	49.	Lith, "Evaluation of the effects on whole body glucose metabolism after single doses of X2000 – A glucose lowering							
00000		agent' Poster presentation, Master thesis in Pharmaceutical Bioscience, Goteborgs University (2008)							
00000000	50.	Ralph et al. "Glucose Modulation of Glucokinase Activation by Small Molecules" Biochemistry 47(17):5028-5036 (2008)							
	51.	Robertson et al. "Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity							
000000000		of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine" Journal of Medicinal Chemistry 28:717-727 (1985)							
00000000	52.	Sarabu et al., "Glucokinase activators as new type 2 diabetes therapeutic agents" Expert Opinion on Therapeutic Patents 18(7):759-768 (2008)							
8	53.	Shorvon, "Pyrrolidone derivatives" Lancet 358(9296):1885-1892 (2001)							
8	54.	Eycken et al., Synthesis of (E)-5-(2-arylviny1)-2-(hetero)arylpyridines, (E)-2-(2-arylviny1)-5-							
00000		methoxycarbonylpyridines and (E,E)-2,5-bis(2-arylviny1)pyridines as polarity and pH probes, 2002, J. Chem. Soc.,							
0000		Perkin. Trans. 2, page 929							
W	55.	West, Anthony R., "Solid State Chemistry and its Applications" Wiley, New York, Pages 358 and 365 (1988)							
- 89	56.								
						.,			
Examine	r	/Paul Zarek/ Date Considered 01/22/2009							
Examin	er: Initia	al if reference considered	l, whether or not cita	tion is in confe	ormance with M	IPEP 609;	draw line th	rough citation if not in	
conformance and not considered. Include copy of this form with next communication to applicant.									